PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
1.790
+0.080 (4.68%)
Nov 21, 2024, 3:02 PM EST - Market open
PharmaCyte Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
13.75M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cosmos Health | 56.04M |
Psychemedics | 20.26M |
Ekso Bionics Holdings | 17.68M |
Vivos Therapeutics | 14.58M |
Can-Fite BioPharma | 667.00K |
Traws Pharma | 226.00K |
PMCB News
- 6 months ago - MyMD Pharmaceuticals Secures Strategic Investments - Business Wire
- 6 months ago - PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease - Business Wire
- 1 year ago - PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc. - Business Wire
- 1 year ago - PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology - Business Wire
- 1 year ago - PharmaCyte Biotech Announces Final Results of Tender Offer - Business Wire
- 1 year ago - PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share - Business Wire
- 1 year ago - PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan - Business Wire
- 2 years ago - PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value - GlobeNewsWire